Araci Rondon, PhD

Araci Rondon is a postdoctoral researcher at the division of Thrombosis and Hemostasis, department of Internal Medicine, LUMC. Her research focuses on Tissue Factor, extracellular vesicles, 3D cellular models, cancer-associated thrombosis and organ-on-a-chip technology.

During her PhD (2012-2017) at Federal University of Rio de Janeiro (UFRJ, Brazil), she evaluated the influence of blood clotting proteins in tumor progression. She studied whether Tissue Factor (TF), the main activator of blood coagulation, is involved in microvesicle release (Rondon, et al., 2018), showed that TF directs secretion of microvesicles and described the pathways involved. Moreover, she studied microvesicles in cancer-associated thrombosis (CAT; Rondon, et al., in preparation) and showed that TF-positive microvesicles promote the onset of thrombosis. During her PhD, she was awarded a grant from the Brazilian government (Science Without Borders, National Council for Scientific and Technological – CNPq) to work with Prof. Dr. Henri Versteeg, LUMC, The Netherlands (December 2013-November 2014).

Since January 2019, she has been recruited by Prof. Henri Versteeg to the Einthoven Laboratory for Vascular and Regenerative Medicine. Recently, she got an ISTH/EHA fellowship award to spend two months in the United Kingdom (April and May 2019) at the laboratory of Dr. Camille Ettelaie (Department of Biomedical and Forensic Science, University of Hull, Kingston upon Hull).

1) Rondon AMR, Kroone C, Kapteijn M, Versteeg HH, Buijs JT. Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis. Accepted in Semin Thromb Hemost. (IF 3.345).
2) Carvalho E, de Almeida VH, Rondon AMR, Possik PA, Viola JP, Monteiro RQ. Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells, Biochem Biophys Res Commun. (IF 2.559), vol. 504 (1), pp. 270-276, September 2018, doi: 10.1016/j.bbrc.2018.08.169
3) de Almeida VH, Almendra LR, Guimarães IS, Rondon AMR, Tilli, TM, de Melo AC, Sternberg C, Monteiro RQ. Positive crosstalk between EGFR and TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer, Oncotarget (IF 5.168), vol. 9 (55), pp. 30594-30609, July 2018, doi: 10.18632/oncotarget.25748
4) Rondon AMR, de Almeida VH, Gomes T, Verçoza BRF, Carvalho RS, König S, Rodrigues JCF, Mermelstein CDS, Versteeg HH, Monteiro RQ. Tissue factor mediates microvesicles shedding from MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. (IF 2.559), vol, 502(1) pp. 137-144, May 2018, doi: 10.1016/j.bbrc.2018.05.136
5) F. G. Gomes, V. Sandim, V. H. Almeida, A. M. R. Rondon, B. B. Succar, E. D. Hottz, A. C. Leal, B. R. F. Verçoza, J. C. F. Rodrigues, P. T. Bozza, R. B. Zingali, and R. Q. Monteiro, Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms, Thromb. Res. (IF 2.779), vol. 159, pp. 24–32, Sep 2017, doi: 10.1016/j.thromres.2017.09.019